Edgewise Therapeutics advances heart drugs with Phase 3 trial planned for EDG-7500 and starts Phase 2 for EDG-15400

Edgewise Therapeutics reported positive Phase 2 results for EDG-7500, a drug targeting hypertrophic cardiomyopathy (HCM), and plans to start a Phase 3 trial by the end of 2026. The company also began dosing patients in a Phase 2 trial for EDG-15400, aimed at treating heart failure with preserved ejection fraction (HFpEF). Financially, Edgewise posted a net income of $1.17 billion in Q3 2026, driven by a $1.35 billion gain from selling its sevasemten program. These developments highlight Edgewise's progress in cardiovascular drug development and strong financial position to support ongoing research.

Edgewise Therapeutics holds a market cap of $4.09 billion and an enterprise value of $3.64 billion as of Nov 05, 2026 04:11 WIB on Pluang. The stock price is $37.45, down 0.61% on the day, with a trading volume of 1,859,204 shares. These figures show a solid market presence as the company advances its cardiovascular drug pipeline.